A low dose of aspirin each day may significantly reduce the chances of colon and rectal cancer returning in certain cases, a new clinical trial has found.

Led by researchers from the Karolinska Institute and Karolinska University Hospital in Sweden, the study involved 626 people with stages 1 to 3 colon or rectal cancer , and specific genetic mutations in the cancer tumors .

Previous studies have suggested that cancers with these mutations – specifically in the PIK3 signaling pathway – could be targeted by aspirin, but this is the first time the hypothesis has been tested in a randomized clinical trial.

Participants who were given aspirin daily were up to 55 percent less likely to see their cancer come back over three years, compared to those taking placebos. For those in the a

See Full Page